|
1
|
Wang J, Luben R, Khaw KT, Bingham S,
Wareham NJ and Forouhi NG: Dietary energy density predicts the risk
of clinically incident type 2 diabetes: the EPIC-Norfolk study.
Diabetes Care. 31:2120–2125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilmot EG, Edwardson CL, Achana FA, Davies
MJ, Gorely T, Gray LJ, Khunti K, Yates T and Biddle SJ: Sedentary
time in adults and the association with diabetes, cardiovascular
disease and death: systematic review and meta-analysis.
Diabetologia. 55:2895–2905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li J, Dong Y, Wu T and Tong N: Differences
between western and Asian type 2 diabetes patients in the incidence
of vascular complications and mortality: A systematic review of
randomized controlled trials on lowering blood glucose. J Diabetes.
Dec 11–2015.Epub ahead of print. View Article : Google Scholar
|
|
4
|
Sena CM, Pereira AM and Seiça R:
Endothelial dysfunction - a major mediator of diabetic vascular
disease. Biochim Biophys Acta. 1832:2216–2231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roberts AC and Porter KE: Cellular and
molecular mechanisms of endothelial dysfunction in diabetes. Diab
Vasc Dis Res. 10:472–482. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drucker DJ: Glucagon-like peptides.
Diabetes. 47:159–169. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luft VC, Schmidt MI, Pankow JS, Hoogeveen
RC, Couper D, Heiss G and Duncan BB; Atherosclerosis Risk in
Communities Investigators: Dipeptidyl peptidase IV and incident
diabetes: the Atherosclerosis Risk in Communities (ARIC) study.
Diabetes Care. 33:1109–1011. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matheeussen V1, Waumans Y, Martinet W, Van
Goethem S, Van der Veken P, Scharpé S, Augustyns K, De Meyer GR and
De Meester I: Dipeptidyl peptidase in atherosclerosis: expression
and role in macrophage differentiation, activation and apoptosis.
Basic Res Cardiol. 108(350)2013. View Article : Google Scholar
|
|
9
|
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS,
Drucker DJ and Husain M: Cardioprotective and vasodilatory actions
of glucagon-like peptide 1 receptor are mediated through both
glucagon-like peptide 1 receptor-dependent and -independent
pathways. Circulation. 117:2340–2350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nyström T1, Gutniak MK, Zhang Q, Zhang F,
Holst JJ, Ahrén B and Sjöholm A: Effects of glucagon-like peptide-1
on endothelial function in type 2 diabetes patients with stable
coronary artery disease. Am J Physiol Endocrinol Metab.
287:E1209–E1215. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Noyan-Ashraf MH, Shikatani EA, Schuiki I,
Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker
DJ and Husain M: A glucagon-like peptide-1 analog reverses the
molecular pathology and cardiac dysfunction of a mouse model of
obesity. Circulation. 127:74–85. 2013. View Article : Google Scholar
|
|
12
|
Vittone F, Liberman A, Vasic D, Ostertag
R, Esser M, Walcher D, Ludwig A, Marx N and Burgmaier M:
Sitagliptin reduces plaque macrophage content and stabilises
arteriosclerotic lesions in Apoe (−/−) mice.
Diabetologia. 55:2267–2275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shah Z1, Kampfrath T, Deiuliis JA, Zhong
J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, et
al: Long-term dipeptidyl-peptidase 4 inhibition reduces
atherosclerosis and inflammation via effects on monocyte
recruitment and chemotaxis. Circulation. 124:2338–2349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsubara J, Sugiyama S, Sugamura K,
Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K,
Konishi M, et al: A dipeptidyl peptidase-4 inhibitor,
des-fluoro-sitagliptin, improves endothelial function and reduces
atherosclerotic lesion formation in apolipoprotein E-deficient
mice. J Am Coll Cardiol. 59:265–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han L, Yu Y, Sun X and Wang B: Exendin-4
directly improves endothelial dysfunction in isolated aortas from
obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res
Clin Pract. 97:453–460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen YX, Wang XQ, Fu Y, Yao YJ, Kong MY,
Nie RQ and Wang JF: Pivotal role of inflammation in vascular
endothelial dysfunction of hyperlipidemic rabbit and effects by
atorvastatin. Int J Cardiol. 146:140–144. 2011. View Article : Google Scholar
|
|
17
|
Drolet MC, Plante E, Battistini B, Couet J
and Arsenault M: Early endothelial dysfunction in cholesterol-fed
rabbits: a non-invasive in vivo ultrasound study. Cardiovasc
Ultrasound. 2(10)2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ,
Zhou Q, Wei W, Zhu HQ and Wang Y: Melatonin attenuates aortic
endothelial permeability and arteriosclerosis in
streptozotocin-induced diabetic rats: possible role of MLCK- and
MLCP-dependent MLC phosphorylation. J Cardiovasc Pharmacol Ther.
21:82–92. 2016. View Article : Google Scholar
|
|
19
|
Zhou B1, Pan Y, Hu Z, Wang X, Han J, Zhou
Q, Zhai Z and Wang Y: All-trans-retinoic acid ameliorated high fat
diet-induced atherosclerosis in rabbits by inhibiting platelet
activation and inflammation. J Biomed Biotechnol. 2012(259693)2012.
View Article : Google Scholar
|
|
20
|
Picatoste B1, Ramírez E, Caro-Vadillo A,
Iborra C, Ares-Carrasco S, Egido J, Tuñón J and Lorenzo O:
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis
primarily by insulin-dependent mechanisms in experimental type-II
diabetes. Potential roles of GLP-1 isoforms. PLoS One.
8:e783302013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao HJ, Xu Q, Zhang GY, Liu Y, Yu T, Li
HY, Yang LN, Wang HY and Xie LB: Therapeutic effects of GLP-1
analog on rats with experimental diabetes mellitus. J Jilin
University. 33:474–479. 2007.
|
|
22
|
Pasterkamp G: Methods of accelerated
atherosclerosis in diabetic patients. Heart. 99:743–749. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Böhm F and Pernow J: The importance of
endothelin-1 for vascular dysfunction in cardiovascular disease.
Cardiovasc Res. 76:8–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cicek FA, Kandilci HB and Turan B: Role of
ROCK upregulation in endothelial and smooth muscle vascular
functions in diabetic rat aorta. Cardiovasc Diabetol. 12(51)2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Piechota A and Goraca A: Influence of
nuclear factor-κB inhibition on endothelin-1 induced lung edema and
oxidative stress in rats. J Physiol Pharmacol. 62:183–188.
2011.PubMed/NCBI
|
|
26
|
Quehenberger P, Bierhaus A, Fasching P,
Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E,
Speiser W and Nawroth PP: Endothelin 1 transcription is controlled
by nuclear factor-kappaB in AGE- stimulated cultured endothelial
cells. Diabetes. 49:1561–1570. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ho FM, Lin WW, Chen BC, Chao CM, Yang CR,
Lin LY, Lai CC, Liu SH and Liau CS: High glucose-induced apoptosis
in human vascular endothelial cells is mediated through NF-kappaB
and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt
eNOS pathway. Cell Signal. 18:391–399. 2006. View Article : Google Scholar
|
|
28
|
Suzuki J, Ogawa M, Muto S, Itai A, Isobe
M, Hirata Y and Nagai R: Novel IkB kinase inhibitors for treatment
of nuclear factor-kB-related diseases. Expert Opin Investig Drugs.
20:395–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arakawa M, Mita T, Azuma K, Ebato C, Goto
H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R and Watada H:
Inhibition of monocyte adhesion to endothelial cells and
attenuation of atherosclerotic lesion by a glucagon-like peptide-1
receptor agonist, exendin-4. Diabetes. 59:1030–1037. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hattori Y, Jojima T, Tomizawa A, Satoh H,
Hattori S, Kasai K and Hayashi T: A glucagon-like peptide-1 (GLP-1)
analogue, liraglutide, upregulates nitric oxide production and
exerts anti-inflammatory action in endothelial cells. Diabetologia.
53:2256–2563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W,
Wang L, He F and Xue Y: The DPP-4 inhibitor sitagliptin attenuates
the progress of atherosclerosis in apolipoprotein-E-knockout mice
via AMPK-and MAPK-dependent mechanisms. Cardiovasc Diabetol.
13(32)2014. View Article : Google Scholar
|
|
32
|
Dai Y, Mehta JL and Chen M: Glucagon-like
peptide-1 receptor agonist liraglutide inhibits endothelin-1 in
endothelial cell by repressing nuclear factor-kappa B activation.
Cardiovasc Drugs Ther. 27:371–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
